Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or its ligand PD-L1, has revolutionized the treatment of non-small cell lung cancer (NSCLC), especially LUAD, significantly prolonging survival in a subset of patients (4–6). Here, PDCD1 is linked to non-small cell lung carcinoma.